We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Moderna (MRNA) Q2 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
In its upcoming report, Moderna (MRNA - Free Report) is predicted by Wall Street analysts to post quarterly loss of $3.47 per share, reflecting an increase of 4.1% compared to the same period last year. Revenues are forecasted to be $124.92 million, representing a year-over-year decrease of 63.7%.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Moderna metrics that are commonly monitored and projected by Wall Street analysts.
The consensus estimate for 'Revenue- Product sales' stands at $102.49 million. The estimate indicates a year-over-year change of -65%.
The collective assessment of analysts points to an estimated 'Revenue- Collaboration revenue' of $12.90 million. The estimate indicates a change of -43.9% from the prior-year quarter.
The average prediction of analysts places 'Revenue- Other revenue' at $21.67 million. The estimate indicates a change of -57.5% from the prior-year quarter.
Analysts expect 'Revenue- Grant revenue' to come in at $5.50 million. The estimate indicates a change of -80.4% from the prior-year quarter.
The combined assessment of analysts suggests that 'Product sales- Rest of world' will likely reach $60.71 million. The estimate suggests a change of -73.7% year over year.
The consensus among analysts is that 'Product sales- Europe' will reach $8.23 million. The estimate indicates a change of -86.3% from the prior-year quarter.
Over the past month, Moderna shares have recorded returns of +2.8% versus the Zacks S&P 500 composite's -0.2% change. Based on its Zacks Rank #2 (Buy), MRNA will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exploring Analyst Estimates for Moderna (MRNA) Q2 Earnings, Beyond Revenue and EPS
In its upcoming report, Moderna (MRNA - Free Report) is predicted by Wall Street analysts to post quarterly loss of $3.47 per share, reflecting an increase of 4.1% compared to the same period last year. Revenues are forecasted to be $124.92 million, representing a year-over-year decrease of 63.7%.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Moderna metrics that are commonly monitored and projected by Wall Street analysts.
The consensus estimate for 'Revenue- Product sales' stands at $102.49 million. The estimate indicates a year-over-year change of -65%.
The collective assessment of analysts points to an estimated 'Revenue- Collaboration revenue' of $12.90 million. The estimate indicates a change of -43.9% from the prior-year quarter.
The average prediction of analysts places 'Revenue- Other revenue' at $21.67 million. The estimate indicates a change of -57.5% from the prior-year quarter.
Analysts expect 'Revenue- Grant revenue' to come in at $5.50 million. The estimate indicates a change of -80.4% from the prior-year quarter.
The combined assessment of analysts suggests that 'Product sales- Rest of world' will likely reach $60.71 million. The estimate suggests a change of -73.7% year over year.
The consensus among analysts is that 'Product sales- Europe' will reach $8.23 million. The estimate indicates a change of -86.3% from the prior-year quarter.
View all Key Company Metrics for Moderna here>>>
Over the past month, Moderna shares have recorded returns of +2.8% versus the Zacks S&P 500 composite's -0.2% change. Based on its Zacks Rank #2 (Buy), MRNA will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>